Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: BRN024
MIFTS: 68

Bronchitis

Categories: Respiratory diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Bronchitis

About this section

MalaCards integrated aliases for Bronchitis:

Name: Bronchitis 12 3 43 15 62 17 71
Chronic Bronchitis 12 74 29 42 15 17
Acute Bronchitis 12 42 62 71 32
Bronchitis, Chronic 74 43 71
Acute Lower Respiratory Tract Infection 71
Acute Bronchitis and Bronchiolitis 12
Lower Respiratory Tract Infection 71
Recurrent Wheezy Bronchitis 12
Ci - Chest Infection 12
Bronchitis Chronic 54
Chest Infection 12
Chest Cold 12

Classifications:

MalaCards categories:
Anatomical: Respiratory diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:6132
ICD9CM 34 466.0 490 491
UMLS 71 C0006277 C0008677 C0149514 more
Sources

Summaries for Bronchitis

About this section
MedlinePlus : 42 Bronchitis is an inflammation of the bronchial tubes, the airways that carry air to your lungs. It causes a cough that often brings up mucus. It can also cause shortness of breath, wheezing, a low fever, and chest tightness. There are two main types of bronchitis: acute and chronic. Most cases of acute bronchitis get better within several days. But your cough can last for several weeks after the infection is gone. The same viruses that cause colds and the flu often cause acute bronchitis. These viruses spread through the air when people cough, or though physical contact (for example, on unwashed hands). Being exposed to tobacco smoke, air pollution, dusts, vapors, and fumes can also cause acute bronchitis. Less often, bacteria can also cause acute bronchitis. To diagnose acute bronchitis, your health care provider will ask about your symptoms and listen to your breathing. You may also have other tests. Treatments include rest, fluids, and aspirin (for adults) or acetaminophen to treat fever. A humidifier or steam can also help. You may need inhaled medicine to open your airways if you are wheezing. Antibiotics won't help if the cause is viral. You may get antibiotics if the cause is bacterial. NIH: National Heart, Lung, and Blood Institute

MalaCards based summary : Bronchitis, also known as chronic bronchitis, is related to haemophilus influenzae and pulmonary disease, chronic obstructive, and has symptoms including cough, chest tightness and shortness of breath. An important gene associated with Bronchitis is ELANE (Elastase, Neutrophil Expressed), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Cefdinir and Bromhexine have been mentioned in the context of this disorder. Affiliated tissues include lung, testes and heart, and related phenotypes are hematopoietic system and homeostasis/metabolism

Disease Ontology : 12 A bronchial disease that is an inflammation of the bronchial tubes. It is caused by bacteria and viruses. The disease has symptom cough with mucus, has symptom shortness of breath, has symptom low fever and has symptom chest tightness.

CDC : 3 Bronchitis occurs when the airways of the lungs swell and produce mucus. That's what makes you cough. Acute bronchitis, often called a "chest cold," is the most common type of bronchitis. The symptoms last less than 3 weeks. Antibiotics are not indicated to treat acute bronchitis. Using antibiotics when not needed could do more harm than good. If you're a healthy person without underlying heart or lung problems or a weakened immune system, this information is for you.

PubMed Health : 62 About acute bronchitis: In acute bronchitis, the lower airways (bronchi) are temporarily inflamed. The inflammation is usually caused by cold viruses, so it often occurs together with other symptoms of a cold. Acute bronchitis causes a cough which might not go away for a while, even after the cold has gone away. Although the cough may be unpleasant and persistent, in otherwise healthy people it usually isn’t anything serious. The symptoms then go away on their own after a few weeks. Treatment with medication usually isn’t necessary. Some medications may help relieve the symptoms a bit.

Wikipedia : 74 Bronchitis is inflammation of the bronchi (large and medium-sized airways) in the lungs that causes... more...

Sources

Related Diseases for Bronchitis

About this section

Diseases related to Bronchitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 894)
# Related Disease Score Top Affiliating Genes
1 haemophilus influenzae 32.4 TNF LACTB CXCL8
2 pulmonary disease, chronic obstructive 32.0 TNF TAC1 SLPI SERPINB1 SERPINA1 RNASE3
3 bronchial disease 31.9 TNF TAC1 RNASE3 IL9 IL6 IL5
4 pulmonary emphysema 31.8 SLPI SERPINB1 SERPINA1 ELANE CXCL8 ALB
5 pneumoconiosis 31.7 TNF SERPINA1 IL6 CXCL8
6 ige responsiveness, atopic 31.6 RNASE3 IL5 IL13
7 hypereosinophilic syndrome 31.6 RNASE3 MPO IL9 IL5 IL13 CXCL8
8 avian influenza 31.6 TNF IL6 CXCL8
9 pulmonary tuberculosis 31.6 TNF IL6 CRP ALB
10 bronchiectasis 31.5 TNF SLPI SERPINA1 MPO ELANE CXCL8
11 pulmonary fibrosis 31.5 MPO IL13 ELANE CXCL8
12 tracheitis 31.5 TNF IL6 CRP
13 chlamydia pneumonia 31.4 TNF IL6 CXCL8 CRP
14 bacterial infectious disease 31.4 TNF IL6 ELANE CXCL8 CRP CFTR
15 pertussis 31.4 TNF IL6 CXCL8 CCL11
16 chlamydia 31.4 TNF IL6 IL5 CXCL8 CRP
17 bronchiolitis 31.3 TNF RNASE3 IL6 IL5 IL13 CXCL8
18 farmer's lung 31.3 TNF SLPI ELANE
19 pulmonary hypertension 31.3 VIP TNF IL6 ELANE CXCL8 CRP
20 laryngitis 31.3 TNF IL6 CRP
21 severe acute respiratory syndrome 31.2 TNF IL6 DDX1 CXCL8 CRP
22 cough variant asthma 31.2 TAC1 RNASE3 IL5 IL13
23 cytokine deficiency 31.2 IL9 IL5 IL13
24 aspergillosis 31.1 TNF IL6 IL5 ELANE CXCL8 CFTR
25 allergic asthma 31.1 RNASE3 IL9 IL5 IL13 CXCL8 CCL11
26 bronchopneumonia 31.0 TNF MPO IL6 ELANE CXCL8 CRP
27 intrinsic asthma 31.0 RNASE3 IL5 IL13
28 exanthem 31.0 TNF MPO IL6 CXCL8 CRP ALB
29 congestive heart failure 31.0 TNF IL6 CRP ALB
30 bronchopulmonary dysplasia 31.0 RNASE3 ELANE CXCL8
31 tonsillitis 30.9 TNF MPO LACTB IL6 CXCL8
32 diphtheria 30.9 TNF IL5 IL13 ALB
33 status asthmaticus 30.9 RNASE3 IL5 IL13 ELANE CXCL8 CCL11
34 dermatitis 30.9 TNF IL6 IL5 IL13 CXCL8 CCL11
35 pneumothorax 30.9 SERPINB1 SERPINA1 CRP
36 pollen allergy 30.9 RNASE3 MPO IL5 IL13
37 gastroenteritis 30.9 TNF RNASE3 LACTB IL6 IL5 CXCL8
38 vaginitis 30.9 TNF SLPI IL6 CXCL8
39 peptic ulcer disease 30.9 TNF CXCL8 ALB
40 gastroesophageal reflux 30.9 VIP TNF MPO IL6 IL5 ELANE
41 rhinitis 30.9 VIP TNF RNASE3 IL9 IL6 IL5
42 asbestosis 30.8 SERPINA1 MPO IL6
43 extrinsic allergic alveolitis 30.8 MPO IL6 ELANE CXCL8 ALB
44 bronchiolitis obliterans 30.8 TNF SLPI MPO IL6 IL13 CXCL8
45 streptococcus pneumonia 30.8 TNF IL6 CXCL8 CRP
46 sarcoidosis 1 30.8 TNF IL9 IL13 CRP CCL11
47 lung abscess 30.8 TNF LACTB IL6 CRP ALB
48 gastric ulcer 30.8 TNF IL6 CXCL8
49 allergic rhinitis 30.8 VIP TAC1 RNASE3 MPO IL9 IL5
50 eosinophilic pneumonia 30.8 RNASE3 IL6 IL5 IL13 CXCL8 CCL11

Comorbidity relations with Bronchitis via Phenotypic Disease Network (PDN): (show top 50) (show all 126)


Acquired Polycythemia Active Peptic Ulcer Disease
Acute Conjunctivitis Acute Cor Pulmonale
Acute Cystitis Acute Ethmoiditis
Acute Frontal Sinusitis Acute Kidney Failure
Acute Maxillary Sinusitis Agammaglobulinemia, X-Linked
Allergic Rhinitis Alzheimer Disease
Anthracosis Anxiety
Aortic Valve Disease 1 Asbestosis
Aspergillosis Asthma
Atrophic Gastritis Benign Essential Hypertension
Bronchiectasis Bronchopneumonia
Cardiac Arrest Cerebral Atherosclerosis
Cerebral Degeneration Cerebrovascular Disease
Chronic Ethmoiditis Chronic Frontal Sinusitis
Chronic Laryngitis Chronic Maxillary Sinusitis
Chronic Pulmonary Heart Disease Chronic Rhinitis
Conjunctivitis Conn's Syndrome
Cystitis Decubitus Ulcer
Deficiency Anemia Diabetic Polyneuropathy
Diaphragm Disease Duodenitis
Dyskinesia of Esophagus Dysthymic Disorder
Encephalopathy Esophageal Candidiasis
Esophageal Disease Esophagitis
Familial Atrial Fibrillation First-Degree Atrioventricular Block
Gastroesophageal Reflux Generalized Anxiety Disorder

Graphical network of the top 20 diseases related to Bronchitis:



Diseases related to Bronchitis
Sources

Symptoms & Phenotypes for Bronchitis

About this section

Symptoms:

12
  • • cough
  • • chest tightness
  • • shortness of breath
  • • low fever

UMLS symptoms related to Bronchitis:


fever, pruritus, recurrent pharyngitis, snoring, coughing

MGI Mouse Phenotypes related to Bronchitis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10 CCL11 CFTR ELANE IL13 IL5 IL6
2 homeostasis/metabolism MP:0005376 10 ALB CFTR CRP ELANE IL13 IL5
3 immune system MP:0005387 9.8 ALB CCL11 CFTR CRP ELANE IL13
4 respiratory system MP:0005388 9.23 CCL11 CFTR IL13 IL5 IL6 SERPINB1
Sources

Drugs & Therapeutics for Bronchitis

About this section

PubMed Health treatment related to Bronchitis: 62

Acute bronchitis gets better on its own without treatment . If you feel weak and ill, it’s best to take it easy for a few days. This also means not doing any sports or other strenuous physical activities. Hot tea or broth is usually considered to have a soothing effect. But there is no scientific proof that drinking a lot more fluids than usual helps, or doesn’t help. Acute bronchitis doesn’t need to be treated with medication. Drugs such as paracetamol (acetaminophen ) or ibuprofen are sometimes a good idea, though, for the relief of cold symptoms such as fever and pain. There hasn’t been enough research on the effectiveness of cough medicines that are designed to make you cough less (cough suppressants) or make it easier to cough up phlegm (expectorants). Because coughing has the important function of getting rid of mucus and foreign objects, cough suppressants should only be used for a limited amount of time, and only for really unpleasant, dry coughs that disrupt your sleep . Herbal medicines might relieve coughs somewhat. Because the symptoms are usually caused by viruses , antibiotics don’t help much in the treatment of acute bronchitis . But they can have side effects and contribute to bacteria becoming resistant. So antibiotics aren’t recommended as a treatment for acute bronchitis.

Drugs for Bronchitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 408)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cefdinir Approved Phase 4 91832-40-5 6915944
2
Bromhexine Approved Phase 4 3572-43-8
3
Temocillin Approved, Investigational Phase 4 66148-78-5
4
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
5
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
6
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
7
Polyestradiol phosphate Approved Phase 4 28014-46-2
8
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
9
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
10
Ofloxacin Approved Phase 4 82419-36-1 4583
11
Losartan Approved Phase 4 114798-26-4 3961
12
Angiotensin II Approved, Investigational Phase 4 4474-91-3, 11128-99-7, 68521-88-0 172198
13
leucovorin Approved Phase 4 58-05-9 6006 143
14
Ephedrine Approved Phase 4 299-42-3 9294
15
Pseudoephedrine Approved Phase 4 90-82-4 7028
16
Sulfamethoxazole Approved Phase 4 723-46-6 5329
17
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
18
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
19
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
20
Budesonide Approved Phase 4 51333-22-3 63006 5281004
21
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
22
Norflurane Approved, Experimental Phase 4 811-97-2
23
Sodium citrate Approved, Investigational Phase 4 68-04-2
24
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
25
Racepinephrine Approved Phase 4 329-65-7 838
26
Atorvastatin Approved Phase 4 134523-00-5 60823
27
Etanercept Approved, Investigational Phase 4 185243-69-0
28
Montelukast Approved Phase 4 158966-92-8 5281040
29
Acetazolamide Approved, Vet_approved Phase 4 59-66-5 1986
30
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
31
Dobutamine Approved Phase 4 34368-04-2 36811
32
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
33
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
34
Bisoprolol Approved Phase 4 66722-44-9 2405
35
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
36
Chlorpheniramine Approved Phase 4 132-22-9, 113-92-8 2725
37
Streptokinase Approved, Investigational Phase 4 9002-01-1
38
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
39
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
40
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
41 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
42
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
43
Thyme Approved Phase 4
44
Ipratropium Approved, Experimental Phase 4 60205-81-4, 22254-24-6 43232 657309
45
Dextromethorphan Approved Phase 4 125-71-3 5360696 5362449
46
Codeine Approved, Illicit Phase 4 76-57-3 5284371
47
Aminophylline Approved Phase 4 317-34-0 9433
48
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
49
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
50
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035

Interventional clinical trials:

(show top 50) (show all 696)
# Name Status NCT ID Phase Drugs
1 Comparison of Cefdinir and Cefdinir/Clavulanic Acid Combination in Treatment of Acute Exacerbation of Chronic Bronchitis (AECB) and Community-acquired Pneumonia (CAP) in Adults Unknown status NCT03400735 Phase 4 Cefdinir 300Mg Capsule
2 Efficacy and Safety of Combined With Andrographolide Sulfonate on the Basis of Conventional Therapy in Patients With Acute Exacerbation of Chronic Bronchitis: a Randomized, Single Blind, Placebo-controlled, Multicenter Study Unknown status NCT03132610 Phase 4 andrographolide sulfonate;andrographolide sulfonate simulation
3 Effect of Vitamin D Supplementation in Young Children With Acute Lower Respiratory Tract Infection at Dr George Mukhari Academic Hospital, Pretoria, South Africa Unknown status NCT02054182 Phase 4 Vitamin D
4 Inspiratory Capacity and HRCT Comparison of Nebulized Arformoterol (Brovana) vs. Dry-powder Inhaler Salmeterol (Serevent) Unknown status NCT01361984 Phase 4 Nebulized arformoterol;Salmeterol
5 Efficacy of Systemic Glucocorticoid in the Treatment of Wheezing in Children Unknown status NCT00494624 Phase 4 prednisolone
6 The Efficacy and Safety of Andrographolide Sulfonate in the Treatment of Acute Bronchitis: a Randomized,Double-blind,Placebo Parallel Controlled,Multicenter Study Unknown status NCT03132623 Phase 4 andrographolide sulfonate;andrographolide sulfonate simulation
7 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Roflumilast on Endothelial Function in Patients With Chronic Obstructive Pulmonary Disease Unknown status NCT01595750 Phase 4 Roflumilast 500;Placebo
8 Use of Roflumilast to Prevent Exacerbations in Fibrotic Sarcoidosis Patients (REFS) Unknown status NCT01830959 Phase 4 Roflumilast;Placebo
9 Effects of Exercise Training on Systemic Inflammation an Muscle Repair According to the Chronic Obstructive Pulmonary Disease Phenotype Unknown status NCT01431625 Phase 4
10 Home Oxygen Therapy in the Ambulatory Treatment of Bronchiolitis Unknown status NCT01216553 Phase 4
11 Randomised, Open-label, Parallel-group Study of the Response to Bronchodilator Treatment in Subjects With Eosinophilic Bronchitis and the Mechanism of Varied Responses to Bronchodilator Treatment. Unknown status NCT02002754 Phase 4 Bambuterol Hydrochloride tablets
12 Temocillin Pharmacokinetics in Paediatrics Unknown status NCT02260102 Phase 4 Temocillin
13 Randomized Double-blind Placebo-controlled Study of add-on Montelukast to Inhaled Budesonide in the Treatment of Nonasthmatic Eosinophilic Bronchitis Unknown status NCT01121016 Phase 4 Montelukast
14 Banlangen Granules Anti-seasonal Influenza Study: a Randomized, Double Blind, Positive and Placebo Controlled，Clinical Study. Unknown status NCT02232945 Phase 4 placebo of oseltamivir phosphate;oseltamivir phosphate;Banlangen (Radix Isatidis) granules;placebo of Banlangen(Radix Isatidis) granules
15 Optimizing Influenza Vaccination in Surgical Oncology Patients Unknown status NCT01698177 Phase 4
16 Evaluation and Treatment of Small Airways in COPD Unknown status NCT02526758 Phase 4 beclomethasone;formoterol;budesonide
17 A Multicenter, Multinational, Randomized, DB Controlled Study of the Efficacy & Safety of Oral Telithromycin 800 mg Once QD for 5 Days vs Azithromycin in the Treatment of Acute Exacerbation of Chronic Bronchitis in Adult Outpatients With COPD. Completed NCT00538148 Phase 4 Telithromycin
18 MAESTRAL - A Prospective, Multinational, Multicenter, Randomized, Double Blind, Double Dummy, Controlled Study Comparing the Efficacy and Safety of Moxifloxacin to That of Amoxicillin Clavulanic Acid for the Treatment of Subjects With Acute Exacerbations of Chronic Bronchitis. Completed NCT00656747 Phase 4 Avelox (Moxifloxacin, BAY12-8039);Amoxicillin clavulanic acid
19 A Canadian Multicenter, Prospective, Open Label, Non-Comparative Study of the Effectiveness and Safety of Oral Telithromycin, 800mg Once Daily in the Treatment of Either Community Acquired Pneumonia or Acute Exacerbation of Chronic Bronchitis in Ambulator Completed NCT00546676 Phase 4 Telithromycin
20 A Double-blind, Placebo Controlled, Randomized Crossover Trial to Characterize the Mucolytic Effectiveness of Tacholiquine® in Chronic Bronchitis Completed NCT02515799 Phase 4 Tacholiquine
21 Study Regarding the Clinical Efficacy of Synatura® in Patients With Chronic Bronchitis Type COPD Completed NCT03623282 Phase 4 Synatura® 15 mL
22 A Randomized, Sham-controlled, Double-blinded Pilot Study to Assess the Effects of High Frequency Chest Wall Oscillation (HFCWO) Therapy in Patients With Chronic Bronchitis Completed NCT00181207 Phase 4
23 Ceftidoren Versus Levofloxacin in the Treatment of Patients With Acute Exacerbations of Chronic Bronchitis (AECB). Multi-centre, Open-label, Randomised, Pilot Study to Evaluate the Effects of the Treatment on Serum Inflammatory Biomarkers Completed NCT01467297 Phase 4 ceftidoren;levofloxacin
24 A Study of the Effect of the ROX Percutaneous Arteriovenous Fistula System (ROX AC1) on Exercise Capacity and Quality of Life in Patients With Chronic Obstructive Pulmonary Disease (COPD) Completed NCT00832611 Phase 4
25 The Effectiveness of Roflumilast in Improving Mucociliary Clearance in Patients With COPD and Chronic Bronchitis Completed NCT03073798 Phase 4 Roflumilast;Placebo
26 An Open-label, Randomized, Multicenter, Clinical Study to Compare the Effects of Telithromycin, Azithromycin and Cefuroxime Axetil on the Penicillin or Macrolide Resistance of Streptococcus Pneumoniae in Patients With Acute Exacerbation of Chronic Bronchitis Completed NCT00132938 Phase 4 telithromycin
27 A Double-blind Placebo-controlled Trial Comparing the Efficacy and Cost-effectiveness of Inhaled Fluticason Propionate Versus Oral N-acetylcysteine in the Treatment of Patients With COPD in General Practice Completed NCT00184977 Phase 4 N-acetylcysteine;fluticasone propionate
28 Efficacy of Losartan in Preventing Progression of COPD Completed NCT00720226 Phase 4 Losartan;Placebo
29 Randomised Cross-over Study to Compare the Effect of Formoterol Plus Tiotropium Versus Formoterol Monotherapy on Breathlessness, Dynamic Hyperinflation and Exercise Tolerance in Moderate-to-severe Stable COPD Patients Completed NCT00680056 Phase 4 Formoterol plus Placebo (Tiotropium);Formoterol plus Tiotropium
30 Effects of Fluticasone On Systemic Markers of Inflammation in Chronic Obstructive Pulmonary Disease Completed NCT00175565 Phase 4 inhaled fluticasone 500 mcg b.i.d.
31 The Value of Antibiotic Treatment of Exacerbations of Hospitalised COPD Patients Completed NCT00170222 Phase 4 doxycycline
32 Clinical Evaluation of a Meropenem Dosage Strategy Based on a Population Pharmacokinetic-pharmacodynamic Model in Lower Respiratory Tract Infection Patients Completed NCT01944319 Phase 4 Routine meropenem therapy;Meropenem therapy based on a PPK and PD model
33 A RANDOMISED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL STUDY TO ASSESS THE BENEFITS OF ACLIDINIUM BROMIDE IN THE RELIEF OF COPD SYMPTOMS INCLUDING COUGH WHEN ADMINISTERED TO PATIENTS WITH COPD Completed NCT02375724 Phase 4 Aclidinium Bromide;Placebo
34 An Open, Multicenter, Non-comparative, Phase IV Trial of Efficacy and Safety of Ketek(Telithromycin) 800mg Completed NCT00261105 Phase 4 telithromycin
35 Clinical Trial for the Assessment of Delayed Antibiotic Treatment Strategies in the Non-complicated Acute Respiratory Tract Infections in General Practice Completed NCT01363531 Phase 4
36 A Two-Week, Randomized, Modified-Blind, Double-Dummy, Parallel-Group Efficacy and Safety Study of Arformoterol Tartrate Inhalation Solution Twice-Daily, Tiotropium Once-Daily, and Arformoterol Tartrate Inhalation Solution Twice-Daily and Tiotropium Once Daily in Subjects With Chronic Obstructive Pulmonary Disease Completed NCT00424528 Phase 4 Arformoterol Tartrate Inhalation Solution;Tiotropium;Arformoterol and Tiotropium;Placebo
37 Effect of Roflumilast on Systemic Markers of Bone Metabolism and Endothelial Function in Patients With Chronic Obstructive Pulmonary Disease Completed NCT01745848 Phase 4 Roflumilast
38 Modified-blind, Randomized, Multicenter, Single Dose, Two-way Crossover Study of Arformoterol Tartrate Inhalation Solution 15 Micrograms Twice A Day Versus 30 Micrograms Once A Day in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Completed NCT00571428 Phase 4 Arformoterol Tartrate Inhalation Solution;Arformoterol Tartrate Inhalation Solution;Placebo
39 A Randomized, Double-Blind, Double-Dummy, Parallel Group 12-Week Comparison of the Efficacy and Safety of Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a Metered-Dose-Inhaler 230/42mcg Twice-daily With Fluticasone Propionate/Salmeterol DISKUS 250/50mcg Twice-daily in Subjects With COPD Completed NCT00633217 Phase 4 Fluticasone Propionate/Salmeterol DISKUS 250/50mcg;Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a MDI 230/42mcg
40 Comparison of Azithromycin or Clarithromycin in 3drugs Protocol of H-pylori Eradication Regimen Completed NCT01667692 Phase 4 azithromycin;clarithmycin
41 Pharmacoeconomic Outcomes of Levalbuterol and Racemic Albuterol in Inpatients Requiring Nebulization (POLARIS) Completed NCT00667797 Phase 4 levalbuterol HCl;albuterol Sulfate
42 Multicenter Controlled Trial on Efficacy of TPEP Device in Adult Patients With Chronic Hypersecretion Completed NCT00700388 Phase 4
43 A Randomized, Double-Blind, Parallel-Group, 16-Week Study to Evaluate the Effect of Fluticasone Propionate/Salmeterol DISKUS® 250/50mcg BID and Placebo on Arterial Stiffness in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Completed NCT00857766 Phase 4 ADVAIR DISKUS™ 250/50mcg
44 A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization Completed NCT01110200 Phase 4 ADVAIR DISKUS 250/50 mg BID;SEREVENT 50 mcg BID
45 Does Vaccinating Health Hutterite Children Against Influenza Prevent Influenza in Other Hutterite Colony Members: A Randomized Cluster Trial Completed NCT00877396 Phase 4
46 Anti-inflammatory Effects of Macrolide Treatment in Influenza Lower Respiratory Tract Infections Completed NCT01779570 Phase 4 Macrolide treatment
47 Effect of Roflumilast on Exacerbation Rate in Patients With COPD Treated With Fixed Combinations of LABA and ICS. A 52-week, Randomised Double-blind Trial With Roflumilast 500 µg Versus Placebo. The REACT Trial Completed NCT01329029 Phase 4 Roflumilast;Placebo
48 Effectiveness of Different Exercise Training Programs to the Profile of COPD Patients Completed NCT01336283 Phase 4
49 Relative Potency of Inhaled Corticosteroids: Validation of a Clinical Model Completed NCT00292838 Phase 4 fluticasone 25, 50, 100, 200 mcg
50 A Randomised Controlled Trial of Atorvastatin as an Anti-Inflammatory Agent in Non-Cystic Fibrosis Bronchiectasis Completed NCT01299181 Phase 4 Atorvastatin

Search NIH Clinical Center for Bronchitis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Acetylcysteine
Aminophylline
aminophylline dihydrate
AMINOPHYLLINE PWDR
cefditoren
CEFTIBUTEN DIHYDRATE
Dornase Alfa
fenugreek seed meal
Fenugreek seed preparation
FENUGREEK SEED PWDR
gemifloxacin mesylate
Guaifenesin
iodinated glycerol
Ipratropium
Ipratropium Bromide
lomefloxacin
oxtriphylline
Theophylline
Theophylline anhydrous
Theophylline calcium salicylate
Theophylline Sodium Glycinate
TRIMETHOPRIM SULFATE

Cochrane evidence based reviews: bronchitis

Sources

Genetic Tests for Bronchitis

About this section

Genetic tests related to Bronchitis:

# Genetic test Affiliating Genes
1 Chronic Bronchitis 29
Sources

Anatomical Context for Bronchitis

About this section

MalaCards organs/tissues related to Bronchitis:

40
Lung, Testes, Heart, Neutrophil, Kidney, Trachea, Skin
Sources

Publications for Bronchitis

About this section

Articles related to Bronchitis:

(show top 50) (show all 21305)
# Title Authors PMID Year
1
Sputum and blood transcriptomics characterisation of the inhaled PDE4 inhibitor CHF6001 on top of triple therapy in patients with chronic bronchitis. 42 61
32197620 2020
2
Factors associated with antibiotic prescribing for acute bronchitis at a university health center. 61 42
32102652 2020
3
Respiratory dysbiosis and population-wide temporal dynamics in canine chronic bronchitis and non-inflammatory respiratory disease. 61 42
31990924 2020
4
Clinical features of chronic bronchitis and genetic risk factors for the development of chronic obstructive pulmonary disease in adolescent smokers. 42 61
32248154 2020
5
Immunogenetic predictors of the development of bronchial obstruction during acute bronchitis in infants. 42 61
32248167 2020
6
Conditions of vulnerability to the inadequate treatment of bronchiolitis. 42
32428154 2020
7
Chronic bronchitis before age 50 years predicts incident airflow limitation and mortality risk. 54 61
19581277 2009
8
Characterisation of phenotypes based on severity of emphysema in chronic obstructive pulmonary disease. 61 54
17573447 2007
9
Determinants of airflow obstruction in severe alpha-1-antitrypsin deficiency. 61 54
17389752 2007
10
Plasma cells and IL-4 in chronic bronchitis and chronic obstructive pulmonary disease. 61 54
17322111 2007
11
[Systemic and lung inflammation in 2 phenotypes of chronic obstructive pulmonary disease]. 54 61
16945263 2006
12
Cystic fibrosis transmembrane conductance regulator function is suppressed in cigarette smokers. 61 54
16497995 2006
13
High seroprevalence of Helicobacter pylori in chronic bronchitis among Chinese population. 61 54
16565595 2006
14
ErbB2 activity is required for airway epithelial repair following neutrophil elastase exposure. 54 61
15923396 2005
15
[Complex search for antiprotease-protease enzyme gene polymorphisms in patients with chronic obstructive pulmonary diseases]. 61 54
15612581 2004
16
Enhanced PMN response in chronic bronchitis and community-acquired pneumonia. 54 61
15516671 2004
17
[Protective and therapeutic effect of pulmonary surfactant on the experimental chronic obstructive pulmonary disease in hamsters]. 54 61
15266830 2004
18
Atypical sinusitis in adults must lead to looking for cystic fibrosis and primary ciliary dyskinesia. 61 54
15126740 2004
19
Marked up-regulation of T lymphocytes and expression of interleukin-9 in bronchial biopsies from patients With chronic bronchitis with obstruction. 54 61
14605067 2003
20
Protease inhibitors of the sulfonamide type: anticancer, antiinflammatory, and antiviral agents. 61 54
12789686 2003
21
The role of neural inflammation in asthma and chronic obstructive pulmonary disease. 54 61
12794061 2003
22
[The study of inflammatory mediators and pulmonary ventilatory capacity in patients with chronic obstructive pulmonary disease]. 54 61
12775264 2003
23
Eotaxin and CCR3 are up-regulated in exacerbations of chronic bronchitis. 61 54
11991282 2002
24
[Eotaxin in induced sputum in patients with asthma and chronic bronchitis: relationship with airway inflammation]. 54 61
11953096 2002
25
Mucin-producing elements and inflammatory cells. 61 54
12568488 2002
26
Interleukin-4 and interleukin-5 gene expression and inflammation in the mucus-secreting glands and subepithelial tissue of smokers with chronic bronchitis. Lack of relationship with CD8(+) cells. 61 54
11751191 2001
27
Pre-protachykinin-A mRNA is increased in the airway epithelium of smokers with chronic bronchitis. 54 61
11555376 2001
28
Bacteriology and beta-lactamase activity in acute exacerbation of chronic bronchitis. 54 61
11468101 2001
29
[Effects of bacterial extract IRS-19 on the concentration of hydrogen peroxide and myeloperoxidase activity in nasal washings of patients with chronic bronchitis]. 54 61
11417179 2001
30
Serum ECP and MPO are increased during exacerbations of chronic bronchitis with airway obstruction. 61 54
10917466 2000
31
Airways inflammation in chronic bronchitis: the effects of smoking and alpha1-antitrypsin deficiency. 61 54
10853853 2000
32
Heat shock proteins mRNA expressions by peripheral blood mononuclear cells in asthma and chronic bronchitis. 61 54
11775547 2000
33
Detection of CFTR gene mutations in patients suffering from chronic bronchitis. 61 54
10767489 2000
34
IL-9 and its receptor in allergic and nonallergic lung disease: increased expression in asthma. 61 54
10629460 2000
35
Pancreatitis and cystic fibrosis gene mutations. 54 61
10503135 1999
36
The significance of sputum ECP levels in differential diagnosis of asthma in children. 54 61
10498044 1999
37
Novel insights into structure and function of MRP8 (S100A8) and MRP14 (S100A9). 61 54
9920411 1998
38
Complete mutational screening of the CFTR gene in 120 patients with pulmonary disease. 61 54
9921909 1998
39
Environmental correlates of impaired lung function in non-smokers with severe alpha 1-antitrypsin deficiency (PiZZ). 54 61
10193391 1998
40
Cellular and molecular characteristics of inflammation in chronic bronchitis. 61 54
9650009 1998
41
Increased levels of elastase and alpha1-antitrypsin in sputum of asthmatic patients. 54 61
9476865 1998
42
Increased VIP-positive nerve fibers in the mucous glands of subjects with chronic bronchitis. 54 61
9412581 1997
43
Blood interleukin-8 production is increased in chemical workers with bronchitic symptoms. 54 61
9358925 1997
44
Human lactoferrin receptor activity in non-encapsulated Haemophilus influenzae. 61 54
9368377 1997
45
Iron-binding proteins in sputum of chronic bronchitis patients with Haemophilus influenzae infections. 54 61
9387961 1997
46
Biochemical and pharmacological characterization of FK706, a novel elastase inhibitor. 54 61
9389382 1997
47
Serum secretory leukoprotease inhibitor levels in chronic bronchitis and Sjögren's syndrome. 54 61
9352624 1997
48
Inhibition of neutrophil elastase-induced interleukin-8 gene expression by urinary trypsin inhibitor in human bronchial epithelial cells. 54 61
9030096 1997
49
Effect of bacterial extract, IRS-19, on the concentration of hydrogen peroxide and myeloperoxidase activity in nasal washings of patients with chronic bronchitis. 54 61
9090443 1997
50
[Interleukin-6 and interleukin-8 in bronchoalveolar lavage fluid material from patients with chronic bronchitis]. 61 54
9273226 1996
Sources

Variations for Bronchitis

About this section
Sources

Expression for Bronchitis

About this section
Search GEO for disease gene expression data for Bronchitis.
Sources

Pathways for Bronchitis

About this section

Pathways related to Bronchitis according to GeneCards Suite gene sharing:

(show all 33)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 13.89 TNF SLPI SERPINB1 SERPINA1 RNASE3 MPO
2
Cytokine Signaling in Immune system 65
Show member pathways
 13.31 TNF IL9 IL6 IL5 IL13 CXCL8
3
PAK Pathway 63
Show member pathways
 13.25 TNF IL9 IL6 IL5 IL13 CXCL8
4
Allograft rejection 1 36
Show member pathways
 12.71 TNF RNASE3 IL9 IL6 IL5 IL13
5
Folate Metabolism 1
Show member pathways
 12.31 TNF MPO IL6 CRP ALB
6
Chemokine Superfamily: Human/Mouse Ligand-Receptor Interactions 64
Show member pathways
 12.28 TNF IL6 CXCL8 CCL11
7
Immune response IFN alpha/beta signaling pathway 22
Show member pathways
 12.24 TNF IL9 IL6 IL5 IL13 CXCL8
8
Transcriptional misregulation in cancer 36
12.21 MPO IL6 ELANE CXCL8
9
Bacterial infections in CF airways 22
Show member pathways
 12.16 TNF IL6 CXCL8 CFTR CCL11
10
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
12.14 TNF TAC1 IL6 IL13 CXCL8
11
Embryonic and Induced Pluripotent Stem Cells and Lineage-specific Markers 64
12.03 SERPINA1 IL6 CFTR ALB
12
IL-17 Family Signaling Pathways 64
Show member pathways
 12.03 TNF IL6 IL5 IL13 CXCL8 CFTR
13
Hematopoietic Stem Cells and Lineage-specific Markers